logo image
search icon
Oligonucleotide Therapy Market

Oligonucleotide Therapy Market Size, Share & Trends Analysis Report By Type (Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi), By Application (Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, Kidney Diseases, Others), By End User (Hospitals, Research Institutes, Others), By Region, And By Segment Forecasts, 2024-2031.

Report ID : 2566 | Published : 2024-10-16 | Pages: 180 | Format: PDF/EXCEL/Power BI Dashbord

Oligonucleotide Therapy Market Size is valued at USD 5.21 billion in 2023 and is predicted to reach USD 19.92 billion by the year 2031 at a 18.6% CAGR during the forecast period for 2024-2031.

Oligonucleotide Therapy Market info

Oligonucleotides are some of the most promising therapeutic mechanisms for a range of hard-to-treat diseases, in particular those caused by genetic mutations. These are Short sequences of artificially created DNA or RNA molecules that attach to matching sequences in messenger RNA or proteins found in specific cells. Subcategories encompass antisense oligonucleotides (ASOs), aptamer RNAs, and RNA interference (RNAi) oligonucleotides. Several pharmaceutical companies were investigating oligonucleotide therapy, a treatment approach that utilizes chemically manufactured small molecule medications resembling nucleotides. These therapies have the potential to exhibit a similar level of specificity as therapeutic antibodies. Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate the cell membrane when administered on their own.

The market for oligonucleotide treatments has grown significantly due to developments in drug delivery technology, nucleic acid chemistry, and a better knowledge of the molecular causes of disease. Antisense oligonucleotides, small interfering RNA (siRNA), microRNA (miRNA) mimics or inhibitors, aptamers, and oligonucleotide-based gene editing tools like CRISPR-Cas9 are important oligonucleotide-based treatment modalities.

Competitive Landscape

Some Major Key Players In The Oligonucleotide Therapy Market:

  • BPCI Biotech Holding
  • SomaGenics Inc
  • Hepion Pharmaceuticals
  • Alnylam Pharmaceuticals
  • Regulus Therapeutics Inc
  • Ionis Pharmaceuticals
  • Gilead Sciences, Inc
  • Santaris
  • InteRNA Technologies B.V.
  • Mirage
  • Biogen
  • Merck KgaA
  • Pfizer Inc.
  • Other Market Players

Market Segmentation:

The Oligonucleotide Therapy Market is segmented on the basis of type, application and end-user. Based on type, the oligonucleotide therapy market is segmented into antisense, ribozymes, aptamers, miRNA, CpG/Immunostimulatory, and RNAi. Based on application, the oligonucleotide therapy market is segmented into infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases and others. The End User segment consists of Hospitals, Research Institutes, and Others.

Based On Type, The Antisense Oligonucleotide Segment Is Accounted As A Major Contributor To The Oligonucleotide Therapy Market.

The antisense oligonucleotide segment is expected to hold the largest share of the market. This segment's benefit is due to the optimization of enhanced delivery, specificity, affinity, and nuclease resistance with reduced toxicity. Antisense oligonucleotide (ASO) therapies have developed into a prominent class of therapeutics. The antisense oligonucleotide segment of the oligonucleotide therapy market is witnessing unique growth due to its potential to target specific disease-causing genes at the molecular level. Antisense oligonucleotides offer a promising approach for treating genetic disorders, neurological diseases, and various types of cancers by modulating gene expression. Advancements in oligonucleotide chemistry, delivery systems, and personalized medicine are driving the development of novel antisense therapies. With ongoing research as well as clinical trials demonstrating the efficacy and safety of antisense oligonucleotides, this segment is poised for continued expansion and adoption in the field of precision medicine and targeted therapeutics.

The Neurodegenerative Disorders Segment Witnessed A Rapid Growth.

Neurodegenerative disorders are indeed a significant focus within the oligonucleotide therapy market segment. The development of oligonucleotide-based therapies for conditions such as Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease is gaining momentum. The potential of oligonucleotide therapy to target specific genes and pathways involved in neurodegeneration has sparked interest in addressing these challenging conditions. As research progresses and clinical trials advance, the neurodegenerative disorders segment is expected to play a crucial role in driving innovation & growth within the oligonucleotide therapy market.

In The Region, The North American Oligonucleotide Therapy Market Holds A Significant Revenue Share.

The North American oligonucleotide therapy market is experiencing robust growth driven by major factors such as increasing research and development activities, rising investments in biotechnology and pharmaceutical sectors, and a growing focus on precision medicine. The region's well-established healthcare infrastructure, strong regulatory framework, and presence of market players contribute to market expansion. Ongoing advancements in oligonucleotide chemistry, delivery technologies, and personalized medicine are shaping the landscape of oligonucleotide therapies in North America. In addition, Asia Pacific is projected to grow at a rapid rate in the global Oligonucleotide Therapy Market due to growing healthcare concerns, especially in the aging population.

Recent Developments:

  • In May 2023, Chinook Therapeutics and Ionis Pharmaceuticals have partnered to jointly research, develop, and market an antisense oligonucleotide therapeutic aimed at treating a rare and severe chronic kidney disease.
  • In March 2023, AusperBio has reported the successful administration of the first dose of AHB-137, an antisense oligonucleotide therapeutic candidate, to a human subject for the treatment of chronic Hepatitis B.

Artificial Intelligence (AI) In Beauty and Cosmetics Market Report Scope

Report Attribute

Specifications

Market Size Value In 2023

USD 5.21 Bn

Revenue Forecast In 2031

USD 19.92 Bn

Growth Rate CAGR

CAGR of 18.6% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Bn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Type, Application, End-User

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Competitive Landscape

BPCI Biotech Holding, SomaGenics Inc, Hepion Pharmaceuticals, Alnylam Pharmaceuticals, Regulus Therapeutics Inc, Ionis Pharmaceuticals, Gilead Sciences, Inc, Santaris, InteRNA Technologies B.V., Mirage, Biogen, Merck KgaA, Pfizer Inc. and Others.

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Oligonucleotide Therapy Market Snapshot

Chapter 4. Global Oligonucleotide Therapy Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis

5.1. by Type & Market Share, 2019 & 2031

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:

5.2.1. Antisense

5.2.2. Ribozymes

5.2.3. Aptamers

5.2.4. miRNA

5.2.5. CpG/Immunostimulatory

5.2.6. RNAi

Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis

6.1. by Application & Market Share, 2019 & 2031

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:

6.2.1. Infectious Diseases

6.2.2. Oncology

6.2.3. Neurodegenerative Disorders

6.2.4. Cardiovascular Diseases

6.2.5. Kidney Diseases

6.2.6. Others

Chapter 7. Market Segmentation 3: by End Users Estimates & Trend Analysis

7.1. by End Users & Market Share, 2019 & 2031

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End Users:

7.2.1. Hospitals

7.2.2. Research Institutes

7.2.3. Others

Chapter 8. Oligonucleotide Therapy Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031

8.1.2. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031

8.1.3. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031

8.1.4. North America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

8.2. Europe

8.2.1. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031

8.2.2. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031

8.2.3. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031

8.2.4. Europe Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

8.3. Asia Pacific

8.3.1. Asia Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031

8.3.2. Asia Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031

8.3.3. Asia-Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031

8.3.4. Asia Pacific Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

8.4. Latin America

8.4.1. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031

8.4.2. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031

8.4.3. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031

8.4.4. Latin America Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031

8.5.2. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031

8.5.3. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by End Users, 2023-2031

8.5.4. Middle East & Africa Oligonucleotide Therapy Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. BPCI Biotech Holding

9.2.2. SomaGenics Inc.

9.2.3. Hepion Pharmaceuticals

9.2.4. Alnylam Pharmaceuticals

9.2.5. Regulus Therapeutics Inc.

9.2.6. Ionis Pharmaceuticals

9.2.7. Gilead Sciences Inc.

9.2.8. Santaris

9.2.9. InteRNA Technologies B.V.

9.2.10. Mirage

9.2.11. Biogen

9.2.12. Merck KGaA

9.2.13. Pfizer Inc.

9.2.14. Other Prominent Players

Segmentation of Oligonucleotide Therapy Market-

Oligonucleotide Therapy Market By Type-

  • Antisense
  • Ribozymes
  • Aptamers
  • miRNA
  • Cpg/Immunostimulatory
  • RNAi

Oligonucleotide Therapy Market seg

Oligonucleotide Therapy Market By Application-

  • Infectious Diseases
  • Oncology
  • Neurodegenerative Disorders
  • Cardiovascular Diseases
  • Kidney Diseases
  • Others

Oligonucleotide Therapy Market By End-User-

  • Hospitals
  • Research Institutes
  • Others

Oligonucleotide Therapy Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the Oligonucleotide Therapy Market Size?

Oligonucleotide Therapy Market is expected to grow at a 18.6% CAGR during the forecast period for 2024-2031.

Regulus Therapeutics Inc, Ionis Pharmaceuticals, Gilead Sciences, Inc, Santaris, InteRNA Technologies B.V., Mirage, Biogen, Merck KgaA, Pfizer Inc. an

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Report License Selection

Determine the appropriate license for your report

Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach